LimFlow®
Transforming CLTI

LF-CA-MKT-34 Rev 2

Global Burden of CLTI and Patient Suffering

In its late stage, Peripheral Artery Disease (PAD) evolves into Chronic Limb-Threatening Ischemia (CLTI) and patients' options become limited. Many of these patients are no longer candidates for endovascular or open surgery and face limb amputation as their only therapeutic option.



There are more than
3.8M
people with CLTI in the US today[1-4]

~264K
new no-option* patients annually
Incidence is 0.4% of US population[7-9]



~150K
US patients suffer lower limb amputation every year [5]

of no-option patients **remain alive and amputation free** (AFS) at 12 months[6]

The Problem with Amputations

Costly[10]

$114,292 hospitalization cost over the 2-year period

Lethal

High postoperative mortality **4-22%**[11]

High mortality at one year **47.93%**[12]

Debilitating[13]

Only **5%** develop mobility post BKA

Only **25%** develop mobility post AKA

One third of patients never leave nursing homes

No-option patients' impaired quality of life[14]



Population average
lower scores mean poorer QoL

SF-36 PCS scores across disease areas

**No-option patients are those in late-stage CLTI where conventional revascularization options are no longer feasible.*

LimFlow® Patients Are Typically No-Option CLTI Patients[15]

To relieve the symptoms of CLTI, patients today are treated primarily with angioplasty or open bypass surgery. In many late-stage patients, however, neither option is feasible due to extensive disease in the target arteries or other anatomical constraints.

No-option CLTI patients are defined as being ineligible for conventional surgical or endovascular options due to severe vascular disease.

They are usually diagnosed with the following medical conditions:

- Rutherford 5 or 6
- Generally high levels of comorbidity including history of smoking, hypertension, diabetes, and end-stage renal disease
- Not eligible for further conventional endovascular or surgical treatments to resolve artery blockage or CLTI
- Doctor's recommendation to consider amputation of the foot or leg
- Lower extremity vascular disease
- Foot ulcers that are not healing

Clinical Evidence to Address the Challenge

Since the first-in-human study in 2013[16], Transcatheter Arterialization of Deep Veins (TADV) with the LimFlow® System has been studied in more than 150 patients globally, targeting CLTI patients typically excluded from other clinical studies.[15,18,19]

PROMISE I Feasibility Study[19]

Prospective, single-arm early feasibility study

32
No-option patients enrolled

7
Participating sites across the U.S.

Primary endpoint
Amputation free survival (AFS)

Patient eligibility
No-option CLTI
Rutherford 5/6
stable dialysis allowed

Baseline characteristics	(n=32)
Age (avg. years)	71 (42-94)
Gender (% male)	66%

Comorbidities	
Diabetes	69%
Type I	13%
Type II	56%
Hypertension	88%
Renal Insufficiency	34%

Target Vein



97% Technical Success Rate

PROMISE II Pivotal Study[15]

PROMISE II, a landmark pivotal trial in CLTI population, was a success and met its primary endpoint.

105
No-option patients enrolled

20
Participating sites across the U.S.

Primary endpoint
AFS at 6 months
Amputation free survival

Patient eligibility
No-option CLTI
Rutherford 5/6
stable dialysis allowed

Baseline characteristics	(n=105)
Mean Age	70 (38-89)
Gender (% male)	69%
African American	15%
Hispanic or Latino	28%

Comorbidities	
Diabetes	77%
Hypertension	91%
Dialysis	18%
Chronic Kidney Disease	39%
Rutherford 5	65%
Rutherford 6	35%

Target Vein



99% Technical Success Rate

> "Sickest population of CLTI patients ever enrolled in a pivotal trial"
>
> *Dan Clair*

No-Option Patients Will Be Redefined

The LimFlow® System is designed to help heal wounds and avoid major limb amputation, while redefining the no-option CLTI patients with excellent clinical outcomes.

PROMISE I 24-Month Results[19]



Limb preservation in no-option patients

Wound healing in patients with **non-healing chronic wounds**



PROMISE II 12-Month Results[20]

Primary Endpoint: 6-month AFS, Limb Salvage, Survival

The NEW ENGLAND JOURNAL of MEDICINE

6-Month Results Published in New English Journal of Medicine



Limb preservation in no-option patients



Wound healing in patients with **non-healing chronic wounds**



The LimFlow® System

LimFlow is a minimally-invasive technology designed to divert blood around diseased arteries in the leg and into the tibial veins that feed the foot, bringing blood and oxygen to starved tissues in the foot.

An abundance of oxygen in the tissue can relieve pain and promote healing of chronic wounds for many patients, improving their quality of life and getting them back to the things they love.





Step 1
The 4F venous catheter is advanced into the tibial vein, while the arterial catheter is navigated simultaneously into the tibial artery.

Step 2
After arriving at the artery to vein crossing point, the venous catheter is deployed and the arterial catheter is rotated for optimal alignment.



Step 3
The embedded needle of the 6F arterial catheter is inserted into the venous catheter's snaring mesh. A micro guidewire is advanced through the crossing needle and a low-profile angioplasty balloon is inflated to allow passage of other devices.



Step 4
The 4F valvulotome is introduced to cut through valves from the crossing point down into the foot, rendering them incompetent and thus facilitating forward flow.



Step 5
Deployment of nitinol-covered crossing and extension stents finalizes the creation of the arterio-venous channel, which rushes blood into the foot.

The LimFlow® System is the only device for TADV that has received **PMA approval from the FDA**

Please refer to the products' IFUs for full procedure recommendation guidelines.

Turning No-Options to New Options

LimFlow® is the only purpose-built TADV system.



The LimFlow ARC® (Arterial Catheter) and V-Ceiver® (Venous Catheter)[17]

The LimFlow ARC and V-Ceiver is the only purpose-built for artery to vein crossing.

The proprietary ARC (arterial catheter) and V-Ceiver (venous catheter) enable optimal visual alignment under fluoroscopy and provide a dependable solution in the setting of below-the-knee artery to vein crossing.

The V-Ceiver's radiopaque mesh fills the vein to provide a distinct visual target and the ARC's embedded crossing needle has a long reach to allow for multiple crossing options.



The LimFlow Vector® (Valvulotome)[17]

The LimFlow Vector is a unique and purpose-made 4Fr, over-the-wire "Push Valvulotome" that is specifically designed to lyse venous valves by pushing downward from the tibial to the distal pedal veins to enable blood to flow into the foot. This makes the process of rendering the valves incompetent more reproducible than the more traditional process of pulling through the valve and is designed for full and immediate pedal arch arterialization.

Vector's cutting basket with forward-facing hooks is designed to preserve the walls of the veins of the foot and avoid vessel trauma by obviating the need for high-pressure ballooning to improve outflow.



LimFlow Covered Extension Stents[17]

Novel electrospun PTFE-covered nitinol extension stents are designed to maximize outflow to the foot by keeping valves in the calf open while blocking smaller veins from taking flow back to the heart.



LimFlow Covered Crossing Stents[17]

The proprietary crossing stent system is designed to create the channel for the blood to move from artery to vein, and offers precise and easy deployment with a distinct nitinol stent design and an enhanced stent delivery system.

The novel tapered crossing stent with electrospun PTFE cover material is specifically designed to optimize sizing for both the artery and vein to maximize flow.

References

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:65-67.
2. The SAGE Group reports that in 2007 approximately 2.8 million people in Western Europe suffered from critical limb ischemia [press release]. Atlanta, GA: SAGE Group. Oct. 20, 2008.
3. Reinecke, H et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. European Heart Journal – Advance Access Published online February 2, 2015.
4. Cost of PVD & Venous Disease – Mary Yost, Sage Group, Presentation at NCVH – June 2016.
5. Creager MA, Matsushita K, Arya S, Beckman JA, Duval S, Goodney PP, Gutierrez JAT, Kaufman JA, Joynt Maddox KE, Pollak AW, Pradhan AD, Whitsel LP. Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association. Circulation. 2021 Apr 27;143(17):e875-e891.
6. M. Imran Ghare, MD et al,Outcomes Among Patients With Chronic Critical Limb Ischemia With No Revascularization Option: Systematic Review and Meta-Analysis J CRIT LIMB ISCHEM 2021;1(3):E85-E92. Epub 2021 August 18.
7. Meta-analysis of the Clinical Effectiveness of Venous Arterialization for Salvage of Critically Ischaemic Limbs; X.W. Lu and al, EJVS 31, 493-499 (2006).
8. Discussion with Dr. Roberto Ferraresi, PCR Peripheral, Nov 2016.
9. Schreve MA, Minnee RC, Bosma J, Leijdekkers VJ, Idu MM, Vahl AC. Comparative Study of Venous Arterialization and Pedal Bypass in a Patient Cohort with Critical Limb Ischemia. Ann Vasc Surg [Internet]. 2014.
10. Stewart CC, Berhaneselase E, Morshed S. The Burden of Patients With Lower Limb Amputations in a Community Safety-net Hospital. J Am Acad Orthop Surg. 2022 Jan 1;30(1):e59-e66
11. Van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early Post-operative Mortality After Major Lower Limb Amputation: A Systematic Review of Population and Regional Based Studies. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):248-57.
12. Beeson SA, Neubauer D, Calvo R, Sise M, Martin M, Kauvar DS, Reid CM. Analysis of 5-year Mortality following Lower Extremity Amputation due to Vascular Disease. Plast Reconstr Surg Glob Open. 2023 Jan 11;11 (1):e4727
13. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC, et al. Quality of life in patients with No-Option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg.
14. Veith Symposium Presentation November 2022: Natural Progression Of High-Risk Chronic Limb Threatening Ischemia (CLTI): The CLariTI Study: How Can Deep Vein Arterialization (DVA) And Pedal Loop Revascularization Alter This Progression, presenter Dr. Anahita Dua.
15. Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, Martínez-Trabal JL, Bunte MC, Lee AC, Mugglin AS, Mills JL, Farber A, Clair DG; PROMISE II Investigators. Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia. N Engl J Med. 2023 Mar 30;388(13):1171-1180.
16. Kum S, Tan YK, Schreve MA, Ferraresi R, Varcoe RL, Schmidt A, et al. Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia. J Endovasc Therapy. 2017;24(5):619-26.
17. LimFlow data on file
18. Schmidt A, Schreve MA, Huizing E, Del Giudice C, Branzan D, Ünlü Ç, Varcoe RL, Ferraresi R, Kum S. Midterm Outcomes of Percutaneous Deep Venous Arterialization With a Dedicated System for Patients With No-Option Chronic Limb-Threatening Ischemia: The ALPS Multicenter Study. J Endovasc Ther. 2020 Aug;27(4):658-665.
19. Clair DG (2021, October 4-7). PROMISE I Update: 2 Year Results [Conference presentation]. VIVA 2021. Las Vegas, NV, United States
20. Clair DG (2023, October 30 – November 2). PROMISE II Update: 1 Year Results [Conference presentation]. VIVA 2023. Las Vegas, NV, United States

www.LimFlow.com
Tel : +1 888 478 7705
Email : info@limflow.com
LimFlow, Inc 3031 Tisch Way | 110 Plaza West San Jose, CA 95128 USA

LimFlow®
Transforming CLTI

LimFlow System **Intended Use/Indications for Use:** The LimFlow System is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. **Contraindications:** Patients with deep venous thrombus in target vein; Patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy. **Warnings and Precautions:** Use in patients with concomitant hepatic insufficiency has not been evaluated; Use in patients with poor cardiac output, e.g., NYHA Class IV, has not been evaluated; Use in pregnant and breastfeeding women has not been evaluated; Implanting the device in the distal half of the calcaneus may result in stent fracture. **Adverse Events:** Acute renal impairment requiring dialysis; Cardiac arrest; Death; Embolization; Graft rupture, trans-graft leak, site leak; Hematoma; Insufficient blood flow to foot; Ischemia; Myocardial infarction; Occlusion; Pain; Peripheral edema; Procedural bleeding; Restenosis of stented segment; Sepsis / Infection; Stent damage, implant migration; Stent graft fracture; Stent graft misplacement, deformation, or migration; The need for surgical or endovascular interventions to rectify an access site problem; Thrombosis; Vessel dissection, perforation, injury; Vessel spasm. Please reference product Instructions for Use for more information regarding indications, warnings, precautions, contraindications and adverse events. **LimFlow ARC Intended Use/Indications for Use:** The LimFlow ARC is intended to facilitate placement and positioning of guidewires and catheters within the peripheral vasculature. **LimFlow V-Ceiver Intended Use/Indications for Use:** The LimFlow V-Ceiver is intended for use in the cardiovascular system to manipulate and retrieve guidewires specified in the IFU. **LimFlow Vector Intended Use/Indications for Use:** The LimFlow Vector is intended for the treatment of vascular disorders and more particularly for excising or disrupting venous valves. **Important Information:** Prior to use, refer to the Instructions for Use for indications, contraindications, suggested procedure, warnings, adverse events, and precautions. **Caution:** Federal (USA) law restricts these devices to sale by or on the order of a licensed healthcare practitioner.